Abstract
Prochlorperazine (PCZ) has been accepted as an effective antiemetic for more than 50 years, although its therapeutic success has been limited by the akathisia that occurs frequently with intravenous (IV) use. Slow infusion of PCZ does not decrease the incidence of these adverse effects. However, no studies have been done to determine whether the incidence of akathisia is reduced by decreasing the dose of PCZ. The purpose of this pilot study was to determine if reducing the IV dose of CPZ reduces the incidence of akathisia while maintaining its therapeutic effectiveness as an antiemetic.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
